MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s41999-021-00504-5

Медицинская библиотека · European geriatric medicine · 2021

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.

Alves Mariana, Fernandes Marília Andreia, Bahat Gülistan, Benetos Athanase, Clemente Hugo, Grodzicki Tomasz, Martínez-Sellés Manuel, Mattace-Raso Francesco, Rajkumar Chakravarthi, Ungar Andrea, Werner Nikos, Strandberg Timo E, EuGMS Special Interest Group inCardiovascular Medicine (Chairpersons A. Ungar and A. Benetos)

СтатьяПоддержка исследования: вне правительства СШАОбзорПеревод в очереди

Аннотация

PURPOSE: In the pathogenesis of severe COVID-19 complications, derangements of renin-angiotensin-aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases.

METHODS

We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are based on a consensus among all authors.

RESULTS

Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins.

CONCLUSIONS

Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, polypharmacy) must be individually considered for each drug group.

Для цитирования: Alves Mariana, Fernandes Marília Andreia, Bahat Gülistan, Benetos Athanase, Clemente Hugo, Grodzicki Tomasz, Martínez-Sellés Manuel, Mattace-Raso Francesco, Rajkumar Chakravarthi, Ungar Andrea, Werner Nikos, Strandberg Timo E, EuGMS Special Interest Group inCardiovascular Medicine (Chairpersons A. Ungar and A. Benetos). Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.. European geriatric medicine. 2021. DOI: 10.1007/s41999-021-00504-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.